دورية أكاديمية
أعرض في EDS

Tofacitinib Treatment Suppresses CD4+ T-Cell Activation and Th1 Response, Contributing to Protection against Staphylococcal Toxic Shock.

التفاصيل البيبلوغرافية
العنوان: Tofacitinib Treatment Suppresses CD4+ T-Cell Activation and Th1 Response, Contributing to Protection against Staphylococcal Toxic Shock.
المؤلفون: Jarneborn A; Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, 413 46 Gothenburg, Sweden.; Department of Rheumatology, Sahlgrenska University Hospital, 413 45 Gothenburg, Sweden., Hu Z; Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, 413 46 Gothenburg, Sweden., Deshmukh M; Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, 413 46 Gothenburg, Sweden., Kopparapu PK; Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, 413 46 Gothenburg, Sweden., Jin T; Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, 413 46 Gothenburg, Sweden.; Department of Rheumatology, Sahlgrenska University Hospital, 413 45 Gothenburg, Sweden.
المصدر: International journal of molecular sciences [Int J Mol Sci] 2024 Jul 07; Vol. 25 (13). Date of Electronic Publication: 2024 Jul 07.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI, [2000-
مواضيع طبية MeSH: Piperidines*/pharmacology , Piperidines*/therapeutic use , Th1 Cells*/immunology , Th1 Cells*/drug effects , Th1 Cells*/metabolism , Pyrimidines*/pharmacology , Pyrimidines*/therapeutic use , Shock, Septic*/drug therapy , Shock, Septic*/immunology , Shock, Septic*/chemically induced , CD4-Positive T-Lymphocytes*/immunology , CD4-Positive T-Lymphocytes*/drug effects , CD4-Positive T-Lymphocytes*/metabolism , Lymphocyte Activation*/drug effects , Staphylococcal Infections*/drug therapy , Staphylococcal Infections*/immunology , Staphylococcal Infections*/microbiology, Animals ; Mice ; Enterotoxins ; Staphylococcus aureus/drug effects ; Cytokines/metabolism ; CD8-Positive T-Lymphocytes/drug effects ; CD8-Positive T-Lymphocytes/immunology ; CD8-Positive T-Lymphocytes/metabolism ; Mice, Inbred C57BL ; Female ; Disease Models, Animal ; Superantigens/immunology
مستخلص: Staphylococcal toxic shock syndrome (STSS) is a rare, yet potentially fatal disease caused by Staphylococcus aureus ( S. aureus ) enterotoxins, known as superantigens, which trigger an intense immune response. Our previous study demonstrated the protective effect of tofacitinib against murine toxin-induced shock and a beneficial effect against S. aureus sepsis. In the current study, we examined the effects of tofacitinib on T-cell response in peripheral blood using a mouse model of enterotoxin-induced shock. Our data revealed that tofacitinib suppresses the activation of both CD4+ and CD8+ T cells in peripheral blood. Furthermore, both gene and protein levels of Th1 cytokines were downregulated by tofacitinib treatment in mice with enterotoxin-induced shock. Importantly, we demonstrated that CD4+ cells, but not CD8+ cells, are pathogenic in mice with enterotoxin-induced shock. In conclusion, our findings suggest that tofacitinib treatment suppresses CD4+ T-cell activation and Th1 response, thereby aiding in protection against staphylococcal toxic shock in mice. This insight may guide the future development of novel therapies for STSS.
References: Nature. 1987 Dec 17-23;330(6149):662-4. (PMID: 3317066)
Scand J Infect Dis. 2010 May;42(5):351-8. (PMID: 20100112)
J Immunol. 1996 Nov 1;157(9):3869-75. (PMID: 8892617)
N Engl J Med. 2021 Jul 29;385(5):406-415. (PMID: 34133856)
Nat Immunol. 2024 Jan;25(1):19-28. (PMID: 38168953)
J Immunol. 2011 Apr 1;186(7):4234-43. (PMID: 21383241)
Immunity. 2012 Apr 20;36(4):542-50. (PMID: 22520847)
Nat Rev Immunol. 2018 Sep;18(9):545-558. (PMID: 29921905)
Pathogens. 2018 May 29;7(2):. (PMID: 29843476)
Shock. 2010 Oct;34(4):358-63. (PMID: 20220566)
N Engl J Med. 2021 Feb 25;384(8):693-704. (PMID: 32678530)
J Emerg Med. 2018 Jun;54(6):807-814. (PMID: 29366615)
PLoS Pathog. 2019 Jun 21;15(6):e1007877. (PMID: 31226163)
J Mol Med (Berl). 2010 Aug;88(8):851-9. (PMID: 20393690)
Pharmacol Ther. 2020 Apr;208:107476. (PMID: 31931100)
Lancet. 2021 May 01;397(10285):1637-1645. (PMID: 33933206)
Science. 1990 May 11;248(4956):705-11. (PMID: 2185544)
Eur J Immunol. 2008 Jan;38(1):48-53. (PMID: 18085667)
Eur J Immunol. 1997 Apr;27(4):825-33. (PMID: 9130631)
Antibiotics (Basel). 2024 Jan 18;13(1):. (PMID: 38247655)
Sci Rep. 2020 Jul 2;10(1):10891. (PMID: 32616791)
Front Cell Infect Microbiol. 2012 Apr 17;2:52. (PMID: 22919643)
Antimicrob Agents Chemother. 2015 Dec;59(12):7367-73. (PMID: 26369979)
Lancet. 1998 Mar 28;351(9107):929-33. (PMID: 9734938)
J Infect Dis. 2011 Aug 1;204(3):348-57. (PMID: 21742832)
Toxins (Basel). 2019 Mar 23;11(3):. (PMID: 30909619)
J Infect Dis. 1994 Jul;170(1):94-9. (PMID: 8014527)
Infect Immun. 2001 Mar;69(3):1256-64. (PMID: 11179286)
Nat Rev Immunol. 2024 Jun;24(6):417-434. (PMID: 38225276)
Clin Infect Dis. 2001 Jan;32(1):76-102. (PMID: 11118387)
J Leukoc Biol. 2001 Jun;69(6):921-7. (PMID: 11404377)
Cell. 2022 Oct 13;185(21):3857-3876. (PMID: 36240739)
Lancet. 2021 Aug 28;398(10302):803-816. (PMID: 34454676)
معلومات مُعتمدة: 523-2013-2750 & 2019-01135 Swedish Medical Research Council; ALFGBG-823941 & ALFGBG-933787 & ALFGBG-770411 Swedish state under the agreement between the Swedish Government and the county councils; 82360396 National Natural science foundation of China; SU-998178 & SU-984612 & SU-984324 & SU-998197 & SU-984331 & SU-998149 Sahlgrenska University Hospitals Research Foundations; 2023-419 Rune och Ulla Amlövs Stiftelse för Neurologisk och Reumatologisk Forskning
فهرسة مساهمة: Keywords: Th1 response; mouse; staphylococcal toxic shock syndrome; tofacitinib
المشرفين على المادة: 87LA6FU830 (tofacitinib)
0 (Piperidines)
0 (Pyrimidines)
0 (Enterotoxins)
0 (Cytokines)
0 (Superantigens)
تواريخ الأحداث: Date Created: 20240713 Date Completed: 20240713 Latest Revision: 20240809
رمز التحديث: 20240809
مُعرف محوري في PubMed: PMC11242597
DOI: 10.3390/ijms25137456
PMID: 39000566
قاعدة البيانات: MEDLINE
الوصف
تدمد:1422-0067
DOI:10.3390/ijms25137456